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Objectives: Mechanical circulatory support (MCS) is often required to stabilize
therapy-refractory cardiogenic shock patients. Left ventricular (LV) unloading by
mechanical ventricular support (MVS) via percutaneous devices, such as with Impella®
axial pumps, alone or in combination with extracorporeal life support (ECLS, ECMELLA
approach), has emerged as a potential clinical breakthrough in the field. While the
weaning from MCS is essentially based on the evaluation of circulatory stability of
patients, weaning fromMVS holds a higher complexity, being dependent on bi-ventricular
function and its adaption to load. As a result of this, weaning from MVS is mostly
performed in the absence of established algorithms. MVS via Impella is applied in several
cardiogenic shock etiologies, such as acute myocardial infarction (support over days) or
acute fulminant myocarditis (prolonged support over weeks, PROPELLA). The time point
of weaning from Impella in these cohorts of patients remains unclear. We here propose
a novel cardiovascular physiology-based weaning algorithm for MVS.
Methods: The proposed algorithm is based on the experience gathered at our
center undergoing an Impella weaning between 2017 and 2020. Before undertaking
a weaning process, patients must had been ECMO-free, afebrile, and euvolemic,
with hemodynamic stability guaranteed in the absence of any inotropic support.
The algorithm consists of 4 steps according to the acronym TIDE: (i) Transthoracic
echocardiography under full Impella-unloading; (ii) Impella rate reduction in single 8–24
h-steps according to patients hemodynamics (blood pressure, heart rate, and ScVO2),
including a daily echocardiographic assessment at minimal flow (P2); (iii) Dobutamine
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stress-echocardiography; (iv) Right heart catheterization at rest and during Exercise-
testing via handgrip. We here present clinical and hemodynamic data (including LV
conductance data) from paradigmatic weaning protocols of awake patients admitted
to our intensive care unit with cardiogenic shock. We discuss the clinical consequences
of the TIDE algorithm, leading to either a bridge-to-recovery, or to a bridge-to-permanent
LV assist device (LVAD) and/or transplantation. With this protocol we were able to wean
74.2% of the investigated patients successfully. 25.8% showed a permanent weaning
failure and became LVAD candidates.
Conclusions: The proposed novel cardiovascular physiology-based weaning algorithm
is based on the characterization of the extent and sustainment of LV unloading reached
during hospitalization in patients with cardiogenic shock undergoing MVS with Impella in
our center. Prospective studies are needed to validate the algorithm.
Keywords: cardiogenic shock, mechanical circulatory support, Impella, weaning algorithm, pressure-volume,
conductance catheter
INTRODUCTION
Cardiogenic shock is a life-threatening low-cardiac-output state
leading to end-organ hypoperfusion, and hypoxia (1). Despite
major advances in the therapies, both medical and surgical,
its in-hospital mortality remains very high (2–5). Mechanical
circulatory support (MCS) for patients with advanced heart
failure has flourished in the past years, supported by the
availability of a multitude of devices (6). These devices have
different hemodynamic peculiarities (7), depending on the
insertion technique and sites of blood withdrawal and return,
on the size of catheters and cannulas as well as on the need of
a gas exchanger (8). Among the MCS devices, extracorporeal
life support (ECLS) plays a central role in cardiogenic shock,
given its reasonable cost and widespread availability in cardiology
as well as in cardiothoracic surgery centers. ECLS is based on
a transcutaneous performed veno-arterial cannulation, which
allows to support circulation at the bedside while oxygenating
blood via a gas exchanger (9). However, the outflow in the
aorta creates an extremely high afterload, detrimental for left
ventricular (LV) contractility as well as dimensions because of
increased wall tension and therefore myocardial oxygen demand
(8). Until a reliable strategy to unload or decompress the
compromised and distended LV can be established, myocardial
recovery will therefore continue to be impaired (10). In
line with this, several modalities of temporarily mechanical
ventricular support (MVS) for LV unloading as well as LV
decompression under ECLS were investigated, such as atrial
septostomy (11), the intra-aortic balloon pump (IABP) (12), the
percutaneous transaortic pulsatile assist device iVAC2 R© (13, 14),
the percutaneous continuous centrifugal pump TandemHeart R©
(6, 15), as well as the Impella family of devices (2.5, CP, 5.0
and 5.5, Abiomed, Danvers, Massachusetts) (16). They differ
with regard to the amount of liters pumped per minute (IABP
0.5, iVAC2L, Impella 2.5 up to 5.5 l/min, TandemHeart up to
5 l/min) as well as for their mode of action (pulsatile vs. non-
pulsatile). The Impella systems are transcutaneously (except from
Impella 5+) deployed axial flow pumps, which directly pump
blood from the LV to the ascending aorta just above the aortic
valve. This approach directly unloads the LV throughout the
cardiac cycle, reducing total mechanical work, and myocardial
oxygen demand, while lowering wall stress and improving
subendocardial coronary blood flow (8, 17). The Impella 5+
pump, which is that most frequently used in our department, is
placed through an arterial cut-down (18). With flow rates of up
to 5 L/min it can offer full support.
While the weaning from MCS is essentially based on the
evaluation of circulatory stability of patients, weaning fromMVS
holds a higher complexity, being dependent on bi-ventricular
function and its adaption to load. As a result of this, weaning
from MVS is mostly performed in the absence of established
algorithms (19–21) and strongly depends on the experience of
the individual centers. Meanwhile, MVS via Impella is applied
in several cardiogenic shock etiologies, such as acute myocardial
infarction (AMICS, support over days) or acute fulminant
myocarditis [prolonged support over weeks, PROPELLA (22)].
PROPELLA was shown to exhibit disease-modifying effects
important for myocardial recovery [i.e., bridge-to-recovery)
when applied in patients with acute fulminant myocarditis as
a prolonged support over several weeks in awake, mobilized
patients (22)]. While the weaning algorithm has been established
for long-term LVAD (23), it does not exist for temporary LV
mechanical support systems.
When considering the timespan of unloading, several
important principles need to be followed: (i) individuality of
chosen strategy, in order to avoid a one-size-fits-all approach;
(ii) “Primum non-nocere,” keeping the time of mechanical
unloading as short as possible, in order to prevent device-
related complications; (iii) efficacy of unloading, i.e., to unload
as long as needed to obtain a sustained impact on LV recovery.
A weaning concept should therefore predict the likelihood of
stable cardiac function when MVS is discontinued. The authors
describe here their institutional experience of 141 cases with the
use of the Impella device (CP or 5+) to support the LV in patients
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with cardiogenic shock. Fifty-two patients died during Impella
support. Eighty-nine patients were tried to get weaned from the
device. We here propose a practical algorithm for the weaning of
cardiogenic shock patients that can be investigated prospectively
in future studies. The possible outcomes of the weaning protocol
are exemplified by original pressure-volume loops from invasive
LV conductance measurements performed in patients admitted
to the authors’ center with cardiogenic shock.
METHODS AND RESULTS
The target population of this weaning concept are patients
with AMICS, decompensated dilative cardiomyopathy, or acute
fulminant myocarditis implanted and supported with an Impella
device for several days (short time support) up to weeks
[prolonged support; (PROPELLA concept) (22)]. The here
proposed algorithm was therefore established in such a cohort
of survivors (n = 89) which had been consecutively admitted
between 2017 and 2020 to the intensive-care unit at the Dept.
of Cardiology in Campus Virchow, Charité-Universitätsmedizin
Berlin, Germany, as described in Table 1. The description of
the algorithm is substantiated by clinical and hemodynamic
data from paradigmatic weaning protocols of patients. The data
regarding the characteristics of the patients were retrieved from
an ongoing study register on the Impella weaning protocol.
Impella Unloading and Implications for
Weaning as Assessed via LV Conductance
At the authors’institution, an exhaustive hemodynamic
assessment with LV-conductance and RV-catheterization
was performed in individual cases during weaning from
Impella. Pulmonary capillary wedge pressure, right atrial
pressure, and pulmonary pressure are determined by right heart
catheterization (Swan-Ganz catheter) and pulmonary vascular
resistance calculated using standard formulas. A conductance
catheter (10-mm spacing, CD Leycom, Zoetermeer, The
Netherlands) is used to assess continuous online measurements
of LV pressure (via a piezoelectric membrane-based high-fidelity
signal) and volume as previously described (24). This catheter
is positioned along the long axis of the LV by the left femoral
artery (7F). The total LV volume signal is calculated from a
maximum of seven segmental volume signals, calibrated with
thermodilution-derived cardiac output as well as hypertonic
saline boluses as previously described and validated (25).
Hemodynamic indices are obtained from steady-state PV loops
during sinus rhythm and at end expiration (26).
Baseline measurements are acquired during full Impella
unloading as well as during minimal Impella support (P2). To
assess LV function during exercise-like conditions, steady-state
PV loops are additionally acquired during handgrip at minimal
Impella support over 2min. Figure 1A (and related.gif files as
online supplement) shows original tracings of Impella patients
during rate change (from full unloading P8 to minimal support
P2 and back) with the typical shift of the loops on the xy plane.
Figure 1B (and related.gif files as online supplement) shows two
patients with different study outcomes: on the right a patient
TABLE 1 | Population characteristics of the n = 89 patients weaned according to
the “TIDE” algorithm.
Patients undergoing a
TIDE-weaning (n = 89)










-Fulminant Myocarditis 16 (18%)
EF
-Pre-interventional
• 44–35% 6 (6.7%)
• 34–15% 52 (58.5%)
• <15% 31 (34.8%)
-Post-interventional
• ≥55% 15 (16.9%)
• 55–45% 11 (12.4%)
• 44–35% 17 (19.1%)
• 34–15% 16 (18%)







-Impella CP 67 (75.3%)
-Impella 5.0/5.5 22 (24.7%)
Duration of Impella-support
-Short-term 4.6 ± 3.0
-Long-term (PROPELLA) 16.9 ± 6.2
Access
-A. femoralis 62 (69.7%)
-A. Subclavia 27 (30.3%)
Weaning failure/LVAD-candidate 23 (25.8%)
Parametric data are presented as mean ± SD. Non-parametric are presented as median
and interquartiles. CVRF, cardiovascular risk factors; AMI, acute myocardial infarction;
LVEF, left ventricular ejection fraction; LVAD, left ventricular assisted device.
who profited from unloading, showing no or minimal increase
of LV end-diastolic pressure (EDP) during handgrip; on the left
a patient who had an abnormal pronounced increase of LV EDP
during handgrip, as a sign of blunted contractile reserve. With
regard to LV EDP, a novel Impella system has been introduced on
the market, called smart assist (Figure 2). This system displays
real-time LVEDP, mean arterial pressure (MAP), and cardiac
power output (CPO) directly on the Impella console, and will
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FIGURE 1 | (A) LV pressure-volume loops (original tracings) from patients during Impella-rate reduction (P2, marked in yellow, on the left) as well as back to maximal
unloading (P8, on the right). The typical shift on the xy plan is observed. (B) LV pressure-volume loops (original tracings) from patients during handgrip. On the right a
patient who profited from unloading, showing no or minimal increase of LV end-diastolic pressure (EDP, red arrow) during handgrip; on the left a patient who had an
abnormal pronounced increase of LV EDP during handgrip, as a sign of blunted contractile reserve.
probably play an important role in the future, especially with
regard to the weaning process.
Surgical Technique for the Implantation of
Impella 5.0 or 5.5
Patients are operated in the hybrid OR. Usually, the right
axillary artery is dissected and a 10-mm vascular graft (Maquet
Hemagard, Getinge Group, Sweden) anastomosed in an end-
to side fashion. The graft is tunneled and externalized through
the skin outside of the skin incision. The Impella 5.0 or 5.5 is
implanted as described elsewhere under fluoroscopic guidance
and echocardiographic control. The incision is closed layer
by layer.
The “TIDE” Algorithm for Weaning
Figure 3 summarizes the proposed algorithm. This algorithm
consists of four chronological steps according to the acronym
TIDE. The first two steps are mandatory. The latter two steps are
indicated in very specific clinical scenarios. The basic principles
of TIDE can be applied to either acute, intermediate or prolonged
Impella support.
Pre-requisite Before Starting With the
Weaning
Before undertaking a weaning process, patients under Impella
support should be afebrile and euvolemic, as reflected by standard
intensive-care imaging (chest x-ray) as well as by adequate
arterial PaO2. In addition, hemodynamic stability, i.e., adequate
heart rate, arterial blood pressure, central venous pressure and
stable rhythm, should be guaranteed in the absence of any
inotropic as well as vasoactive agents, while parameters of end
organ dysfunction should be fully recovered to baseline values.
At the authors’institution, all echocardiographic assessments are
performed with a GE Vivid S70 ultrasound system.
Step One, Transthoracic Echocardiography
Under Full Impella Unloading
Echocardiographic hemodynamic monitoring is the basic
technique to assess LV functional stability for the management
of patients before and during (27, 28), Impella, PROPELLA or
ECMELLA weaning. It is essential to anticipate either recovery
or weaning failure, a lesson learned from decision-making
algorithms in ECLS (21), as well as in LVAD recipients (29).
With regard to patients with ECMELLA, the weaning from
ECLS is almost merely based on the evaluation of circulatory
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FIGURE 2 | The novel Impella smart assist, displaying real-time LV end-diastolic pressure and mean arterial pressure on the Impella console.
FIGURE 3 | The “TIDE” algorithm for weaning from mechanical circulatory support.
stability with ECMO flow to a minimum rate of 1.2–1.5 L/min,
while the Impella support is usually discontinued in a separate
weaning step.
In principle, a precise assessment of heart function is
only feasible at minimal flow (P2). However, minimal flow
(P2) echocardiography can be performed once the overall
cardiac kinetic as well as LV-size show an improvement (LV
end-diastolic diameter below 60mm), while mitral and tricuspid
regurgitation should be mild or less under full unloading.
The echocardiographic evaluation consists of three steps,
investigating 3 different compartments as described below:
(a) Left heart function. LV chamber dimensions should
be evaluated according to the guidelines on chamber
quantification (30). In addition, LV ejection fraction (LV EF)
should be assessed using the biplane Simpson’s method and
the LV outflow tract (LVOT) velocity-time integral (VTI)
using a pulsed waveform Doppler in an apical 5-chamber
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view. The ratio between early mitral inflow velocity and mitral
annular early diastolic velocity (E/e’) should be assessed.
(b) Pulmonary circulation. Tricuspid regurgitation assessment
via continuous-wave Doppler with concomitant estimation
of the systolic pulmonary arterial pressure (sPAP) should be
performed, including estimation of mean pressure (mPAP),
and pulmonary vascular resistance (PVR) by standardDoppler
echocardiography formulas.
(c) Right heart function. RV dimensions and functionality should
be evaluated e.g., via RV fractional area change (FAC), RV
free wall longitudinal strain or tricuspid annular plane systolic
excursion (TAPSE).
Moving to step two of the algorithm can be considered if the
patient has no end-stage cardiac disease and has partially or fully
recovered from the initial cardiac dysfunction, as assessed by the
abovementioned indices. Figure 4 illustrates the artifact that is
introduced into the images because of the electromagnetic motor
of the pump positioned in the ascending aorta. This artifact
interferes in 2-dimensional Doppler images of the heart (31).
Step Two, Impella Rate Reduction,
Including Daily Minimal Flow
Echocardiography
After step one evaluation is completed, Impella rate is decreased
in single steps (e.g., P8 to P7, and so on) with the goal of
achieving half of the baseline support with stable hemodynamics.
At every rate, echocardiographic changes in the abovementioned
three compartments as well as hemodynamic responses (blood
pressure, heart rate, lactate and central venous O2 saturation)
are monitored over the total procedure. If, at any period in the
weaning protocol, RV or LV distension occurred or significant
hypotension or increase in heart rate is observed, the weaning
protocol is stopped and Impella support is returned back to full
flow. Overall, Impella support should be reduced by single 8–24-
h steps and then daily re-evaluated. During the daily, minimal
flow (P2) echocardiographic examination following parameter
and their acute changes will play a major role in the clinical
decision-making process:
(a) Left heart. LV chamber dimensions, LV EF and E/e’. In order
to discontinue the Impella support, LVEF should be above
30–35%. A LVOT VTI increase with a lower level of Impella
support is the Doppler echocardiographic demonstration of
bi-ventricular recovery (Figure 5).
(b) Pulmonary circulation. sPAP, mPAP, and PVR, in order to
exclude an overt pulmonary hypertension.
(c) Right heart. RV dimensions, RV FAC, RV free wall LS or
TAPSE, in order to evaluate long-term RV stability.
In case the three compartments show stable LV and RV function,
as well as pulmonary circulation, the weaning is concluded with
the discontinuation of Impella support.
In following cases, the weaning should proceed into step three
of the algorithm:
(a) Uncertain results, i.e., discrepancy between LV EF and
forward stroke volume changes during Impella results, such
as an increase between 10 and 20% of forward stroke volume
despite increase of LV EF above 5%, or high estimated
filling pressure (E/e’) or LV EDP according to the smart
assist console.
(b) Early device-related complications, either technical such as
a device defect, or clinical, such as stroke, leg ischemia, or
significant hemolysis.
Step three should clarify, if a new device with a different insertion
site (switch to an axillary approach) or an alternative unloading
approach (e.g., iVAC2l) is needed, or the discontinuation of the




Figure 6 shows a summary of a dobutamine stress-
echocardiographic examination of a patients after 4 weeks
of LV unloading as a treatment for a fulminant non-viral
myocarditis. For detection of inotropic response in patients
during MCS, stages of 5–10min are used, starting from 10
up to 40 µg/kg/min, in order to fully recruit the inotropic
reserve in such patients under beta-blocker therapy (32). After
each increment in dobutamine dose, a period of 5min before
starting the image acquisition will allow the hemodynamic
response to develop. As it is not feasible to assess all possible
parameters during stress, priority should be given to parameters
of contractile reserve, such as changes in LV volumes, LV EF
and RV EF and LVOT VTI. Global contractile reserve is often
defined as an increase by >5% in LVEF while a flow reserve is
defined as an increase in forward stroke volume by ≥20% (32).
As the purpose of the dobutamine test is to assess contractile
reserve, atropine co-administration, associated with higher rate
of complications, is not indicated inMCS patients (32). In dilated
non-ischaemic cardiomyopathy, patients with significant LV EF
improvement during dobutamine infusion have a better survival
rate, fewer hospitalizations for HF, and an increase in the LVEF
during follow-up (33). The presence of inotropic contractile
reserve is also associated with a decrease in the need for cardiac
transplantation (34) and correlates inversely with the extent
of interstitial fibrosis and scarred myocardium (35). Patients
with a contractile reserve will be prepared for device removal,
while patients with no reserve should be discussed within the
heart-team sessions for LVAD-implantation or transplantation.
In the last case, or in case of uncertain forward flow reserve, an
additional invasive hemodynamic characterization (step four)
should be initiated (Figure 7).
Step Four, Exercise-Testing via Handgrip
During Invasive Catheterization
In awake patients being evaluated for LVAD-implantation or
transplantation, as well as blunted contractility reserve, a right-
heart catheterization should be performed, including assessment
of changes in cardiac index, PAP, pulmonary capillary wedge
pressure (PCWP) and pulmonary vascular resistance (PVR)
during handgrip compared to baseline, in order to assess cardiac
and pulmonary circulation reserve. At the authors’institution,
an exhaustive hemodynamic assessment including both LV-
conductance and RV-catheterization is performed, as described
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FIGURE 4 | Impella’s artifacts interfere in 2-dimensional echo and Doppler images of the heart.
FIGURE 5 | The increase in LVOT VTI with a lower level of Impella support is the Doppler echocardiographic demonstration of bi-ventricular recovery.
above (Figure 1). Of note, not all the patients were awake
during the beginning of weaning assessment, for this reason
only the awake patients performed a handgrip during the
weaning procedure.
Outcome of TIDE-Algorithm Driven
Weaning Process
A total of 141 patients with AMICS, decompensated dilative
cardiomyopathy, or acute fulminant myocarditis were supported
with an Impella device for several days (short time support;
4.6 + 3.0 days; Table 1) up to weeks (prolonged support;
PROPELLA concept; 16.9 + 6.2 days; Table 1) (22). 89
patients underwent a weaning process. 66/89 (74.2%) passed
the weaning program successfully. In about one fifth of these
cases a single weaning attempt was sufficient, while the rest
of patients had to undergo several attempts until the device
could be safely explanted. Successful weaning was associated
with a reduction of NT B-natriuretic peptides (BNP) levels
and an improvement in LV EF (Table 1). 32/89 (25.8%) of
patients did not pass the weaning program successfully. These
patients showed a minimal change in LVEF only, despite a
similar drop in NT-BNP levels compared to the successfully
weaned patients (66.8 vs. 64.1%, respectively; n.s.), indicating
that Impella-induced unloading was sufficient in both groups.
However, even a repetition of the program did not allow
a stable weaning in these cases. Thereby, most of these
patients did not pass Step two of TIDE. These patients became
LVAD candidates.
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FIGURE 6 | Summary of a dobutamine stress-echocardiographic examination of a patients after 4 weeks of LV unloading as a treatment for a fulminant non-viral
myocarditis.
FIGURE 7 | Workflow for clinical decision-making after dobutamine-stress echocardiography.
DISCUSSION
In patients with cardiogenic shock due to acute myocarditis,
temporary MCS may provide bridge to durable MCS, transplant,
or recovery. ECLS causes on the long-term LV dilation due to
retrograde arterial flow and, therefore, increased afterload, while
triggering mechanotransduction and inflammation pathways
(36, 37). Left ventricular (LV) unloading by percutaneous
transvalvular axial-flow devices, such as the Impella family
of devices [2.5, CP, and 5+ (16)], has therefore emerged as
a potential clinical breakthrough in the field. LV unloading
by Impella was shown to exhibit disease-modifying effects
important for myocardial recovery (i.e., bridge-to-recovery)
when applied in patients with acute fulminant myocarditis as
a prolonged support over several weeks in awake, mobilized
patients [prolonged Impella or PROPELLA (22)]. These findings
are in line with data from previous studies on the short- and
median term beneficial effects at molecular, neurohormonal,
cellular and structural level during LV unloading with durable
devices (38). However, the duration of the “prolonged” Impella
concept has not yet been standardized, i.e., the timepoint of
weaning from Impella in this cohort of patients remains unclear,
with most cardiac arrest centers performing weaning from MCS
in the absence of clear guidelines or algorithms (19–21). The
authors describe here their institutional experience with Impella-
mediated LV venting in cardiogenic shock patients, while
proposing a novel cardiovascular physiology-based weaning
algorithm (TIDE). We discuss the clinical consequences of the
TIDE algorithm, leading to either a bridge-to-recovery, or to a
bridge-to-permanent LVAD and/or transplantation.
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Percutaneous Transvalvular Axial-Flow
Devices in Cardiogenic Shock
Percutaneous unloading using a transaortic LV assist device
in cardiogenic shock has become increasingly popular and has
therefore been widely adopted in the last years. Most of data in
literature are derived from studies focusing on acute myocardial
infarction complicated by cardiogenic shock (AMICS). However,
a strong clinical evidence of the use of such devices based
on randomized multicentric trials is still missing. A recently
published analysis of outcomes for 15,259 US patients with
acute myocardial infarction complicated by cardiogenic shock
supported with the Impella device, showed a wide variation in
outcomes across included centers. Survival was higher when
Impella was used as first support strategy, when combined with
invasive hemodynamic monitoring, and at centers with higher
Impella implantation volume (>7 Impella cases per year). In
hospitals in the bottom quintile of Impella implantation volume,
mortality was 70%, but only 24% in the highest quintile (39). Of
note, the systematic use of shock protocols positively impacted
on survival in AMICS, probably because of a more appropriate
selection of the timing of device implantation. In a small, single-
center, non-randomized study Impella CP initiation prior to PCI
was associated with higher survival rates at discharge and up
to 1 year in AMICS patients presenting with high risk for in-
hospital mortality (40). Furthermore, unloading the left ventricle
before reperfusion in STEMI was feasible as well as safe (41).
The utilization of Impella in cardiogenic shock after myocardial
infarction was also associated with less complications compared
to ECLS (42). Finally, the strategy of percutaneous LV unloading
using a transaortic LV assist device in combination with VA-
ECLS improved outcome in an all-comers cohort compared
to what predicted by established risk scores, such as SAVE or
SAPS-II (43).
Evidence on Early-Stage LV Unloading in
Acute Myocarditis
Acute fulminant myocarditis is characterized by a transient
contractility impairment, which accounts not only for the tissue
damage but rather for a myocardial stunning similar to the one
after reperfusion in AMI. While stunning is reversible, it can
take several days to weeks to resolve (44). It is the result of an
oxidative stress on the ground of microvascular ischemia and
an unfavorable remodeling due to inflammation as well as to
increased mechanical wall stress (36). Based on the consistent
finding of good long-term survival outcomes for acute fulminant
myocarditis, an aggressive hemodynamic support in the early
stages of the disease seems to consistently impact on long-
term survival outcomes, being therefore crucial (16, 45). MCS
not only offers a bridge to recovery but also could hasten
the process of recovery. Several mechanisms are involved in
promoting myocardial recovery in the setting of mechanical
circulatory support. The most important is related to the increase
of perfusion pressure through increasing coronary flow which
seems to play a central role in VA-ECMO therapy (46). In
line with that, LV unloading via a percutaneous device such as
Impella, could reduce the wall stress not only via a reduction of
microvascular resistance but also reducing the mechanical work
while minimizing the myocardial oxygen demand (44). Although
epidemiological data demonstrate an increase in the incidence
of cardiogenic shock secondary to myocarditis during the last
decade, the mortality remained the same, possible due to the
increased utilization of mechanical circulatory support (45).
Before Starting With the Weaning Trial
The determination of the ideal conditions to start the weaning
trial is the key point for the outcome and has been relatively
underestimated by the studies so far. The existing data are mainly
based on ECLS studies, where the mean duration of support
was ranging from 3 up to 8 days (20, 47). Of importance, the
main factor which allows the beginning of a weaning trial is
the reversibility of the etiology that led to cardiogenic shock
(48). Therefore, therapeutic interventions such as reperfusion,
specific myocarditis therapy or electrical stabilization should
have been performed to improve the course of cardiogenic
shock (49). Furthermore, the patient should have recovered
from the hemodynamic conditions which lead to MCS, i.e.,
high volume overload as well as high dose of inotropic agents
(49), having a baseline mean arterial pressure (MAP) of >60
mmHg in the absence or at low doses of vasoactive agents and
a pulsatile arterial waveform maintained for at least 24 h (49–
52). According to the Extracorporeal Life Support Organization
(ELSO) guidelines, recovery of hepatic function is essential before
to perform any attempt to wean patients from ECLS (52).
However, it does not seem necessary to wait for the recovery of
kidney function (53).
Predicting Weaning Success
As the use of MCS in cardiogenic shock increases, the
identification of reliable indicators of successful MCS weaning
constitutes an issue in patient selection and treatment planning.
The existing data derive from observational studies with
patients who underwent ECLS support and durable LVAD (47).
Diverse clinical, echocardiographic, invasive, and non-invasive
hemodynamic parameters as well as biomarkers have been
evaluated. Small studies have assessed the ability of pulse pressure
(5) and functional parameters of sublingual microcirculation
[such vessel density, (54)] to predict successful weaning. Among
the biomarkers only lactate and lactate clearance are reported
to be associated with outcome (55). Furthermore, invasive
markers (off pump values) such as cardiac index >2.4l/min/m2,
pulmonary capillary wedge pressure<18mmHg (56) and cardiac
power output CP > 0.6W, CPI> 0.4 W/m2 (56) were showed to
correlate well with myocardial recovery. Echocardiography plays
a central role in the weaning process. Parameters reflecting the
systolic function of left and right ventricle such as aortic velocity
time integral, LVEF, mitral annulus peak systolic velocity, 3D-
RVEF as well as RV free wall strain own a high predictive value.
Additionally, LV and RV dilation were found as independent
negative predictive factors. The use of the aforementioned
indicators to assess the success of weaning in patients with
Impella is relatively arbitrary and reveals the need of more robust
evidence in the context of randomized trials.
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Weaning Strategies: The Role of
Echocardiography and Invasive
Catheterization
The knowledge gained in the field so far is derived from
two echocardiography based ECLS weaning studies, one based
on transthoracic (50) and one on transoesophageal (57)
examination. In the first one (50), as soon as the patient
was considered hemodynamically and respiratory stable, ECLS
support was gradually reduced to 66% initially and then to 33%
of initial support for 10–15min and finally to a minimum of 1–
1.5 l/min. In case of blood pressure drop the weaning trial was
discontinued and ECLS flow returned to a full support. Criteria to
remove the ECLS were functional recovery and good toleration of
weaning trial, meaning a LVEF>20% and an aortic VTI>10 cm.
The second weaning study (57) consisted of four steps, in
line with the protocol described in the current work. Initial
baseline RV and LV function and volumes were measured under
full ECLS support. In the second step the ECLS support was
gradually decreased in single steps of 0.5 l/min with the goal of
achieving the half of the initial flowwithmaintenance of adequate
hemodynamics. At every flow level, RV and LV function,
dimensions and hemodynamic responses were monitored over
5–10min to allow estimation of ventricular function and volume
status. If, at any period in the weaning protocol, RV or LV
distension occurred or significant hypotension or increase in
heart rate was observed, the weaning protocol was stopped.
and ECLS support was returned to full flow. The third step
included volume challenge with albumin 5% meanwhile the
ECLS support was reduced at a minimum of 1.2–1.5 l/min. In
last step LV an RV function was evaluated under inodilators
(dobutamine or milrinone over 4–6 h) in order to evaluate the
RV function before LVAD implantation. In case of recovery of
RV and LV function ECLS could be removed. It is worth noting,
that the weaning protocol should be adjusted depending on the
type of mechanical support, as ECLS leads to overloading of
the left ventricle and unloading of the right ventricle, while a
percutaneous transvalvular approach such as with the Impella
unloads mainly the left ventricle. ECLS weaning protocols should
therefore include a careful assessment of the function of the
right ventricle and aim at preserving hemodynamic stability
under minimal mechanical support, while weaning protocols
from an Impella support should focus on evaluation of left
ventricular function and contractile reserve, as described in
Figure 7.
While several studies in literature have described the effect
of most common MCS and MVS on LV and RV hemodynamics
by pressure-volume analysis (8, 17, 58), exhaustive conductance
catheter investigation of biventricular function do not play a
major in the weaning process from MCS/MVS. This is certainly
due to the low availability of the system in real-world centers, as
well as for the invasive approach needed for such an investigation.
In line with this, the pressure-volume data from individual
patients reported in the current manuscript are to be understood
as physiology-based insight in the unloading process and its
potential outcomes.
Limitations
The proposed algorithm was developed at a single institution
and needs further clinical evidence. The validation of the TIDE
algorithm and the analysis of the predictive factors that may
identify the candidate of LVAD implantation are the subject
of an ongoing study and were not the purpose of the current
manuscript. It cannot be used for right ventricular weaning
strategies. It had not been investigated in other LV unloading
devices. Outcome of patients andweaning success highly depends
on the experience of the single center with the device being
utilized. As a large university hospital, we cannot exclude a
selection bias, and we therefore here underline the need for
multi-center studies.
Conclusion
The proposed novel cardiovascular physiology-based weaning
algorithm is based on the characterization of the extent and
sustainment of LV unloading reached during hospitalization in
patients with acute fulminant myocarditis and cardiogenic shock
undergoing MCS with a percutaneous transvalvular axial flow
device. However, its validity in the context of several types of
MCS, as well as of different pathogenesis of cardiogenic shock,
needs further investigation.
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